Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

The Pharmaceutical Compliance Forum's 2024 Annual Members Meeting

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

MoFo partner Adam Braverman will moderate a panel titled "Precision Medicines: 'The Right Drug for the Right Patient at the Right Time' - What Every Compliance Professional Should Know" at the Pharmaceutical Compliance Forum 2024 Annual Members Meeting on March 15, from 10:45 - 11:30 a.m. EST, in New York.

MoFo partner Adam Braverman will moderate a panel titled "Precision Medicines: 'The Right Drug for the Right Patient at the Right Time' - What Every Compliance Professional Should Know" at the Pharmaceutical Compliance Forum 2024 Annual Members Meeting on March 15, from 10:45 - 11:30 a.m. EST, in New York. Adam will lead a conversation on the complex ethical and regulatory considerations pharmaceutical companies must navigate to ensure patient safety, data privacy, and ethical conduct due to the increased focus on gene therapy and Precision Medicine. To learn more about the Pharmaceutical Compliance Forum, visit the <a href="https://www.pharmacomplianceforum.org/" target="_blank">event website</a>.<hr>

Sign Up

Adam L. Braverman is a partner in Morrison Foerster’s Investigations + White Collar Defense practice. Adam formerly served as an Associate Deputy Attorney General for the U.S. Department of Justice (DOJ) and as the U.S. Attorney for the Southern District of California. Adam has represented public and private companies and their executives in complex government-facing probes, which have resulted in favorable outcomes and declinations by the government. He also represents boards of directors and companies in conducting complex internal investigations and compliance reviews. He has particular experience representing clients in investigations related to the False Claims Act (FCA) and Anti-Kickback Statute (AKS), procurement fraud, bribery, and national security, among other issues. He has successfully represented public companies and their boards of directors and officers in SEC enforcement actions and securities class actions. Adam also designs compliance policies on behalf of corporate clients and conducts trainings to ensure best practices in light of recent revisions to DOJ’s Evaluation of Corporate Compliance Programs and Corporate Criminal Enforcement Policies.Additionally, Adam advises clients on all aspects of complex commercial litigation in federal and state trial and appellate courts and in arbitration. He has represented clients in actions involving breaches of contracts and a wide array of complex commercial disputes.Before joining MoFo, Adam spent 13 years at DOJ, where he served in senior-level leadership positions in multiple administrations. As an Associate Deputy Attorney General, he advised the Deputy Attorney General on litigation and policy matters and was designated to coordinate DOJ’s efforts to investigate and prosecute fraud in connection with COVID-19 and CARES Act relief funds. During his tenure, he worked closely with all of DOJ’s law enforcement agencies, other federal agencies, INTERPOL, and state and local law enforcement agencies and associations.Adam also served as U.S. Attorney for the Southern District of California, where he managed one of the largest and busiest U.S. Attorney’s Offices in the country, comprised of nearly 300 employees. In this role, Adam was responsible for enforcing all violations of federal law in the district and defending the nation in all civil lawsuits. Prior to becoming U.S. Attorney, Adam was an Assistant U.S. Attorney and Deputy Chief, leading complex investigations and prosecutions of large-scale international criminal organizations. Prior to joining the government, Adam was an associate at a leading global law firm, where he dedicated his practice to civil litigation, white collar criminal cases, and internal investigations.Adam received his J.D. from the George Washington University School of Law and his B.A., cum laude, from the George Washington University.<h4>Representative Experience</h4><ul><li>A major U.S. defense contractor in an FCA matter involving allegations of fraudulent billing and workplace misconduct by a former employee in which the government declined to intervene and the relator dismissed the matter.</li><li>A small U.S. defense contractor in an FCA matter involving allegations of fraudulent billing and misrepresentations on grant applications in which the government closed its investigation.</li><li>A major U.S. defense contractor in an FCA matter involving allegations of fraudulent billing in which the court granted a motion to dismiss the matter.</li><li>An international defense contractor in a DOJ criminal investigation of allegations of bribery, wire fraud, and money laundering in which the government closed its investigation.</li><li>A major U.S. defense contractor in an investigation involving allegations of U.S. sanctions violations in which the government took no action.</li><li>A large for-profit college in multiple investigations involving allegations that the company improperly received and used federal funds in which the government closed its investigation.</li><li>An individual investigated by DOJ for alleged criminal violations of International Traffic in Arms Regulations in which the government closed its investigation.</li><li>A public company in a Securities Exchange Act Section 14(a) challenge to a proxy statement alleging material omissions in which the court denied a preliminary injunction and granted a motion to dismiss the case.</li><li>Healthcare organizations and private equity firms in FCA matters involving fraudulent billing and kickback allegations. </li><li>A professional sports team in a government investigation in which the government closed its investigation.</li><li>An entity in connection with the sale of a portion of a professional sports team.</li></ul>

The Pharmaceutical Compliance Forum's 2024 Annual Members Meeting

15 Mar 2024 10:45 AM - 11:30 AM EDT